AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32877825 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine plus Quetiapine
Number of subjects: 122
Study 32877825 — intervention group
Group type: COMPARATOR
Intervention: Psychomotor Retardation presence
Number of subjects: 122
Study 35507447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic walking program (24 weeks)
Number of subjects: 58
Study 35507447 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 58
Study 34582575 — intervention group
Group type: EXPERIMENTAL
Intervention: Light (>500 lux) + exogenous melatonin (LSC)
Number of subjects: 9
Study 34582575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark (<5 lux) + exogenous melatonin (DSC)
Number of subjects: 9
Study 34582575 — intervention group
Group type: COMPARATOR
Intervention: Light (>500 lux) (LS)
Number of subjects: 9
Study 33539672 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose lowering (target HbA1c concentration of ≤48 mmol/mol [6.5%])
Number of subjects: 11140
Study 32489539 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial Pivot (MP) TKA
Number of subjects: 80
Study 32489539 — intervention group
Group type: COMPARATOR
Intervention: Posterior-Stabilized (PS) TKA
Number of subjects: 80
Study 34411745 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive patient education (two, one-hour treatment sessions)
Number of subjects: 202
Study 34411745 — intervention group
Group type: COMPARATOR
Intervention: Placebo patient education (two, one-hour treatment sessions)
Number of subjects: 202
Study 32932330 — intervention group
Group type: EXPERIMENTAL
Intervention: CYD‐TDV booster dose
Number of subjects: 250
Study 32932330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 35965825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion (1.5 mg/kg lidocaine 10 minutes prior to induction, followed by 2 mg/kg/h until the end of surgery)
Number of subjects: 82
Study 35965825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine infusion
Number of subjects: 82
Study 35965825 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 82
Study 34967575 — intervention group
Group type: EXPERIMENTAL
Intervention: Kali Haldi and aloe vera gel mixture, 3 times a day for 3 months
Number of subjects: 42
Study 34967575 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of hydrocortisone and hyaluronidase for 6 weeks with oral antioxidant supplements for 3 months
Number of subjects: 42
Study 34559394 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (10 mg)
Number of subjects: 65
Study 34559394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 34816727 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive monitoring strategies (serial 3 short-duration monitors: 24-/48-hour ECG monitors)
Number of subjects: 346
Study 34816727 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive monitoring strategies (serial 3 longer-term monitors: 14-day ECG monitors)
Number of subjects: 346
Study 34816727 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-duration monitors
Number of subjects: 346
Study 34816727 — intervention group
Group type: EXPERIMENTAL
Intervention: Serial long-term (7-14 day) intermittent monitors accumulating at least 28 days of annual monitoring
Number of subjects: 346
Study 34816727 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardiac monitor (ICM)
Number of subjects: 346
Study 34816727 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring duration
Number of subjects: 346
Study 34323446 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative optic nerve sheath diameter measurements
Number of subjects: 0
Study 34323446 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative optic nerve sheath diameter measurements
Number of subjects: 0
Study 35636802 — intervention group
Group type: EXPERIMENTAL
Intervention: elobixibat (10 mg)
Number of subjects: 100
Study 35636802 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 100
Study 33844469 — intervention group
Group type: EXPERIMENTAL
Intervention: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5) plus Bevacizumab (10 mg/kg IV on days 1 and 15)
Number of subjects: 105
Study 33844469 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (150 mg/m2/day PO on days 1–5) and Irinotecan (50 mg/m2/day IV on days 1–5)
Number of subjects: 105
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index preparations
Number of subjects: 20
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index version of 'Legume with CHO' lunch
Number of subjects: 20
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index version of 'Chicken with corn' lunch
Number of subjects: 20
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index salads
Number of subjects: 20
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycaemic index desserts
Number of subjects: 20
Study 32960632 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycaemic index main dishes
Number of subjects: 20
Study 34469766 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR monitoring
Number of subjects: 6004
Study 34469766 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 6004
Study 32517729 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian diet (VD)
Number of subjects: 90
Study 32517729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MD)
Number of subjects: 90
Study 32517729 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with butyrate (MD-Bt)
Number of subjects: 90
Study 32680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Strength Training (IMST)
Number of subjects: 12
Study 32680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (EMST)
Number of subjects: 12
Study 32680804 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal Function Exercises (VFE)
Number of subjects: 12
Study 34227397 — intervention group
Group type: COMPARATOR
Intervention: No beta-blocker
Number of subjects: 6077
Study 34227397 — intervention group
Group type: COMPARATOR
Intervention: >0% to 12.5% beta-blocker dose
Number of subjects: 6077
Study 34227397 — intervention group
Group type: COMPARATOR
Intervention: >25% to 50% beta-blocker dose
Number of subjects: 6077
Study 34227397 — intervention group
Group type: EXPERIMENTAL
Intervention: >12.5% to 25% beta-blocker dose
Number of subjects: 6077
Study 34227397 — intervention group
Group type: COMPARATOR
Intervention: Full-dose beta-blocker
Number of subjects: 6077
Study 32481469 — intervention group
Group type: EXPERIMENTAL
Intervention: Total bile acid to platelet ratio (TPR)
Number of subjects: 118
Study 32481469 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartate aminotransferase to platelet ratio index
Number of subjects: 118
Study 32481469 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrosis index based on 4 factors
Number of subjects: 118
Study 32481469 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell distribution width to platelet ratio
Number of subjects: 118
Study 35436232 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers module
Number of subjects: 811
Study 35436232 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers module completion
Number of subjects: 811
Study 35231678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 375
Study 35231678 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 375
Study 32072344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder/air polishing every 30 days (group 1)
Number of subjects: 19
Study 32072344 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine powder/air polishing at baseline and on day 90 (group 2)
Number of subjects: 19
Study 32072344 — intervention group
Group type: COMPARATOR
Intervention: Water irrigation every 30 days (group 3)
Number of subjects: 19
Study 35708758 — intervention group
Group type: EXPERIMENTAL
Intervention: (1 → 3)‐β‐d‐Glucan (BDG) guidance
Number of subjects: 339
Study 35708758 — intervention group
Group type: COMPARATOR
Intervention: Targeted antifungal therapy driven by culture results (Control)
Number of subjects: 339
Study 33348031 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative long-term abdominal drains (LTADs)
Number of subjects: 14
Study 33348031 — intervention group
Group type: COMPARATOR
Intervention: Large volume paracentesis (LVP)
Number of subjects: 14
Study 32108122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 50 mg tramadol
Number of subjects: 150
Study 32108122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate high-fat (LCHF) diet (4% carbohydrates; 77% fat; 19% protein)
Number of subjects: 24
Study 33801247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic low-carbohydrate high-fat (LCHF) diet
Number of subjects: 24
Study 33801247 — intervention group
Group type: COMPARATOR
Intervention: National Food Agency recommended control diet (44% carbohydrates; 33% fat; 19% protein)
Number of subjects: 24
Study 32348306 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline tartrate plus Quitline-counselling (n = 196)
Number of subjects: 392
Study 32348306 — intervention group
Group type: COMPARATOR
Intervention: Quitline-counselling alone (n = 196)
Number of subjects: 392
Study 34605192 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 0
Study 34605192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 36273312 — intervention group
Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Training (HIIT), n=15
Number of subjects: 45
Study 36273312 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (COM), n=15
Number of subjects: 45
Study 36273312 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=15
Number of subjects: 45
Study 34748549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition-Targeted Exercise (CTE) with Cognitive Behavior Therapy (CBT)
Number of subjects: 60
Study 34748549 — intervention group
Group type: COMPARATOR
Intervention: Symptom-Targeted Exercise (STE) with Cognitive Behavior Therapy (CBT)
Number of subjects: 60
Study 35639197 — intervention group
Group type: EXPERIMENTAL
Intervention: Siponimod (2 mg/day)
Number of subjects: 779
Study 35639197 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 779
Study 36498624 — intervention group
Group type: EXPERIMENTAL
Intervention: Polaprezinc-containing therapy (PQT)
Number of subjects: 100
Study 36498624 — intervention group
Group type: COMPARATOR
Intervention: Bismuth-containing therapy (BQT)
Number of subjects: 100
Study 35486296 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Risers intervention
Number of subjects: 240
Study 35486296 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 240
Study 34659809 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 64
Study 34659809 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 64
Study 34659809 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 64
Study 35672572 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (PPL)
Number of subjects: 160
Study 35672572 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 160
Study 34065997 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder applied from postoperative day 1
Number of subjects: 109
Study 34065997 — intervention group
Group type: COMPARATOR
Intervention: No abdominal binder or similar devices
Number of subjects: 109
Study 34065997 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic abdominal binder applied from postoperative day 1 (age ≥ 50 subgroup)
Number of subjects: 109
Study 34065997 — intervention group
Group type: COMPARATOR
Intervention: No abdominal binder or similar devices (age ≥ 50 subgroup)
Number of subjects: 109
Study 32253896 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional multicomponent training (MFT), N=15
Number of subjects: 37
Study 32253896 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional multicomponent training (MTT), N=14
Number of subjects: 37
Study 32253896 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG), N=8
Number of subjects: 37
Study 35373687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ida My Hearing Explained Tool (IMHET)
Number of subjects: 51
Study 35373687 — intervention group
Group type: COMPARATOR
Intervention: Audiogram
Number of subjects: 51
Study 34574738 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity tracker
Number of subjects: 11
Study 34574738 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device characteristics
Number of subjects: 11
Study 34574738 — intervention group
Group type: COMPARATOR
Intervention: Questionnaire scores
Number of subjects: 11
Study 34574738 — intervention group
Group type: EXPERIMENTAL
Intervention: Device acceptability level
Number of subjects: 11
Study 34574738 — intervention group
Group type: COMPARATOR
Intervention: Healthcare professionals' perception
Number of subjects: 11
Study 32270959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal exercises with upper limb movements (ARM)
Number of subjects: 20
Study 32270959 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal activation with leg movements (LEG)
Number of subjects: 20
Study 36085065 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided meditation (Yoganidra) for 6 weeks
Number of subjects: 80
Study 34826381 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV (12 μg of mRNA, two 0.6 mL doses, days 1 and 29)
Number of subjects: 39680
Study 34826381 — intervention group
Group type: EXPERIMENTAL
Intervention: CVnCoV
Number of subjects: 39680
Study 34826381 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl, two 0.6 mL doses, days 1 and 29)
Number of subjects: 39680
Study 34826381 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39680
Study 33246159 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequentist linear mixed effect (LME) modelling
Number of subjects: 0
Study 33246159 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian hierarchical modelling
Number of subjects: 0
Study 33246159 — intervention group
Group type: COMPARATOR
Intervention: Crude change
Number of subjects: 0
Study 33246159 — intervention group
Group type: COMPARATOR
Intervention: SEKOIA JSW change
Number of subjects: 0
Study 33246159 — intervention group
Group type: COMPARATOR
Intervention: OAI JSW change
Number of subjects: 0
Study 32133780 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 150 mg oral daily from the first trimester
Number of subjects: 1790
Study 32133780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1790
Study 32133780 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk group (no specific intervention mentioned)
Number of subjects: 1790
Study 34267115 — intervention group
Group type: EXPERIMENTAL
Intervention: PFCL-assisted drainage through preexisting break
Number of subjects: 52
Study 34267115 — intervention group
Group type: COMPARATOR
Intervention: Posterior retinotomy to drain subretinal fluid
Number of subjects: 52
Study 33603941 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (TIVA) with remifentanil and propofol (n = 35)
Number of subjects: 72
Study 33603941 — intervention group
Group type: COMPARATOR
Intervention: Volatile Anesthesia (VA) with propofol induction and maintenance with desflurane and nitrous oxide (n = 37)
Number of subjects: 72
Study 32994235 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation programme for the MRF service
Number of subjects: 222
Study 35078079 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-oral treatment
Number of subjects: 400
Study 35078079 — intervention group
Group type: COMPARATOR
Intervention: Intravenous treatment
Number of subjects: 400
Study 32150762 — intervention group
Group type: EXPERIMENTAL
Intervention: macitentan
Number of subjects: 85
Study 32150762 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 85
Study 36050653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab after temozolomide treatment
Number of subjects: 18
Study 36050653 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks)
Number of subjects: 18
Study 33730151 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone/Ketamine
Number of subjects: 130
Study 33730151 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 130
Study 32088302 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (G‐CSF) administered for 5 days every 3 months for 4 cycles (group A, n = 50)
Number of subjects: 100
Study 32088302 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (group B, n = 50)
Number of subjects: 100
Study 32243907 — intervention group
Group type: COMPARATOR
Intervention: IP-sham
Number of subjects: 69
Study 32243907 — intervention group
Group type: COMPARATOR
Intervention: RP-sham
Number of subjects: 69
Study 32243907 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-cathodal tDCS
Number of subjects: 69
Study 32243907 — intervention group
Group type: EXPERIMENTAL
Intervention: RP-anodal tDCS
Number of subjects: 69
Study 35063311 — intervention group
Group type: EXPERIMENTAL
Intervention: SKIP‐IT intervention (narrative and picture‐based smoking cessation intervention delivered via text messages)
Number of subjects: 28
Study 35063311 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 28
Study 33367833 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright IDEAS (BI) problem-solving skills training (PSST)
Number of subjects: 154
Study 35972531 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of caffeine
Number of subjects: 18
Study 35972531 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg of caffeine
Number of subjects: 18
Study 35972531 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 18
Study 34151724 — intervention group
Group type: EXPERIMENTAL
Intervention: internet-based Cognitive Behavioral Therapy (iCBT)
Number of subjects: 10
Study 34151724 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual (TAU)
Number of subjects: 10
Study 36190062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 gm intravenously 30 minutes before surgery)
Number of subjects: 96
Study 36190062 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 96
Study 36190062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 96
Study 36190062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 34294807 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% red shading screen
Number of subjects: 0
Study 34294807 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% black shading screen
Number of subjects: 0
Study 34294807 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% silver shading screen
Number of subjects: 0
Study 34294807 — intervention group
Group type: COMPARATOR
Intervention: Full sun control
Number of subjects: 0
Study 32588919 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training of the ankle plantarflexors (30 sessions: 10 supervised and 20 unsupervised home sessions over 10 weeks)
Number of subjects: 64
Study 32588919 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training of the ankle plantarflexors
Number of subjects: 64
Study 32588919 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 64
Study 34410011 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Care Bridge (CCB) intervention
Number of subjects: 306
Study 34410011 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 306
Study 33543267 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 12
Study 33543267 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar Breeze thermal rehabilitation machine (PB)
Number of subjects: 12
Study 33543267 — intervention group
Group type: COMPARATOR
Intervention: Passive rest (PASS)
Number of subjects: 12
Study 32560634 — intervention group
Group type: EXPERIMENTAL
Intervention: TPRK
Number of subjects: 126
Study 32560634 — intervention group
Group type: COMPARATOR
Intervention: FS-LASIK
Number of subjects: 126
Study 35403350 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide XR 2.0 mg weekly
Number of subjects: 100
Study 35403350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 35403350 — intervention group
Group type: COMPARATOR
Intervention: Exenatide XR vs Placebo
Number of subjects: 100
Study 33291700 — intervention group
Group type: EXPERIMENTAL
Intervention: Chili (2 g)
Number of subjects: 30
Study 33291700 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35387718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cecal ligation and puncture (CLP) model
Number of subjects: 2
Study 35387718 — intervention group
Group type: COMPARATOR
Intervention: Sham group (control)
Number of subjects: 2
Study 32146123 — intervention group
Group type: EXPERIMENTAL
Intervention: Water irrigant
Number of subjects: 121
Study 32146123 — intervention group
Group type: COMPARATOR
Intervention: Saline irrigant
Number of subjects: 121
Study 32748028 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically predicted reduction in HbA1c (%) instrumented by AMPK variants
Number of subjects: 391199
Study 34686616 — intervention group
Group type: EXPERIMENTAL
Intervention: Single CHO mouth rinse (8% maltodextrin)
Number of subjects: 12
Study 34686616 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight CHO mouth rinses (8% maltodextrin)
Number of subjects: 12
Study 34686616 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution (noncaloric juice)
Number of subjects: 12
Study 35280154 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐Term Assessment of Risk and Treatability (START)
Number of subjects: 50
Study 33539915 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173